NovelBeam Technology(SH:688677) Huachuang Securities·2025-11-20 13:43Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 57 yuan [4][8]. Core Insights - The company reported a significant increase in performance for Q3 2025, with total revenue reaching 448 million yuan, a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also up by 40.03% [2][4]. - The growth in Q3 2025 was particularly strong, with revenue of 182 million yuan, representing an 85.26% increase year-on-year, and a net profit of 62 million yuan, which is a 130.72% increase [2][4]. - The company has launched a new employee incentive plan, granting 1 million restricted shares at a price of 25 yuan per share, focusing on employees related to overseas business [4][8]. Financial Performance Summary - For the first three quarters of 2025, the company's medical endoscope and optical businesses drove revenue growth, with the endoscope business alone seeing a 100% increase in Q3 [4][8]. - The after-sales service revenue also grew significantly, reaching 60 million yuan, an 80% increase year-on-year, with international after-sales contributing 53 million yuan [4][8]. - The gross profit margin remained stable, supported by the increase in sales volume and effective coordination between domestic and overseas production [4][8]. Financial Projections - The company forecasts total revenue of 601 million yuan for 2025, with a year-on-year growth rate of 35.8%, and net profit of 184 million yuan, reflecting a growth rate of 36.1% [4][9]. - Earnings per share (EPS) are projected to be 1.54 yuan in 2025, with corresponding price-to-earnings (P/E) ratios of 30, 24, and 20 for the years 2025, 2026, and 2027 respectively [4][9].